Purpose Dyslipidemia and impaired glucose metabolism are the main health issues of growing prevalence and significant high healthcare cost, requiring novel prevention and/or therapeutic approaches. Epidemiological and animal studies revealed that olive oil is an important dietary constituent, inducing normolipidemia. However, no studies have specifically investigated the polyphenol-rich water extract of olives (OLWPE), generated during olive oil production. Methods In the present work, we initially examined the effect of OLPWE on animals' metabolic parameters. Rats fed with a high-fat diet were treated with three different doses of OLPWE for 4 months. Additionally, bioavailability was explored. Afterwards, OLWPE's metabolic effect was explored in humans. Healthy volunteers consumed microencapsulated OLWPE for 4 weeks, in a food matrix [one portion (30 g) of a meat product]. Results High-fat-fed rats developed a metabolic dysfunction, with increased LDL and insulin levels and decreased HDL; this syndrome was significantly impaired when treated with OLWPE. Treated rats had increased total plasma antioxidant capacity, while several phenolic compounds were detected in their blood. These findings were also verified in humans that consumed OLWPE, daily, for 4 weeks. Interestingly, in individuals with elements of cardio-metabolic risk, OLWPE consumption resulted in reduced glucose, insulin, total cholesterol, LDL and oxLDL levels. Conclusions Our data clearly show that OLWPE can improve glucose and lipid profile, indicating its possible use in the design of functional food and/or therapeutic interventions.
Introduction
Impaired glucose tolerance and lipid metabolism are the most common metabolic dysfunctions in humans and they have been closely associated with obesity. The latter is now recognized as a chronic disease of alarming incidence Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0039 4-018-1807-x) contains supplementary material, which is available to authorized users.
(close to 40% of adults in the world are overweight or obese) [1] . Obesity complications can further result in several life-threatening pathological conditions. In fact, the various metabolic disorders (such as dyslipidemia and impaired glucose tolerance) usually seen in centraltype obesity [2] , together with increased blood pressure, characterize a pro-inflammatory state [2] [3] [4] , leading to an increased likelihood of insulin resistance/type 2 diabetes, and atherosclerosis/cardiovascular disease [3] . These metabolic and inflammatory alterations, together with a resulting pre-thrombotic state [4] , may result in premature death. The obesity-induced cascade of events characterizes a pathophysiological state, commonly referred as "metabolic inflammation", a low-grade inflammation, triggered by adipose tissue hypertrophy and hyperplasia and subsequent hypoxia. As a result, there is an altered lipid metabolism and an increased production of several hormones, chemokines and cytokines and coagulation factors that lead to hyperinsulinemia, β pancreatic cell dysfunction, type II diabetes, increased sodium uptake, vasoconstriction and hypertension, increased lipoprotein synthesis, gluconeogenesis and dyslipidemia, endothelial dysfunction, atherosclerosis and clotting disorders and ultimately to coronary heart disease. The collective cluster of (central) obesity, dyslipidemia, impaired glucose tolerance/insulin resistance and hypertension is commonly referred to as the "metabolic syndrome" [5] .
Obesity, due to its high global prevalence and comorbidities, has become an international healthcare priority, with the major aim being the early diagnosis of metabolic dysfunction and improvement of body weight and adverse metabolic disturbances (mainly lipids and glucose), by dietary modifications and pharmaceutical interventions. The cost of the latter is extremely high [6, 7] , and therefore, alternative approaches, which may improve the above elements, are of great importance, both for the health of the patients and for a possible reduction of the pharmaceutical expenditure.
A great variety of animal and human epidemiological studies report beneficial effects of olive oil and/or olive-olive oil polyphenol extracts [8] [9] [10] on glucose and lipid metabolism. However, during olive harvesting and olive oil production, a water phase is also produced, commonly discarded. This phase is rich in olive (poly)phenols, which distribute between the oil and water phase, as a result of the time of olive paste malaxation and temperature. Here, we studied the effect of a fresh microencapsulated olive water phenolic extract (OLWPE) in a rat model of diet-induced obesity and extended our study (as a proof of principle) in a healthy human population that consumed this extract in the context of a food matrix. Our findings clearly show that OLWPE can ameliorate main metabolic parameters, such as fasting glucose levels and lipid profile, indicating its possible dietary and/or therapeutic use.
Methods

Isolation and characterization of OLWPE
Olive water total polyphenolic extract (OLWPE) was obtained using olive mill wastewater, immediately collected during olive oil production through centrifugation, passing through a multilevel ion-exchange proprietary resin filter (patent nos. GR20030100295 20030708 and WO2005003037) and elution with ethanol (75%); ethanol was subsequently fully evaporated and the water extract was concentrated in a rotor evaporator. The total content of polyphenols was estimated by the Folin-Ciocalteu method [11] that has been modified to use small volumes. Briefly, 20 µL sample was mixed with 80 µL of distilled water, 400 µL of Na 2 CO 3 (10% Na 2 CO 3 in 0.85 N NaOH), and 500 µL of Folin-Ciocalteu reagent (10%). The mixture was left to stand for 1 h in the dark and absorbance was measured at 750 nm. The total phenolic profile was expressed as Trolox (a water-soluble analog of vitamin E) equivalents.
The specific composition of the polyphenolic content was obtained using NMR spectroscopy and liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS/MS). NMR spectroscopy experiments were conducted on a Bruker Avance III NMR spectrometer, operating at 500 MHz for the proton nucleus. OLWPE extracts' NMR analysis was performed by mixing 100 µL of the sample with 400 µL MeOD. The mixture was vigorously shaken and then placed in a 5 mm NMR tube, where 1D (zg30, zgpr) and 2D (gCOSY, gHSQC, gHMBC) NMR spectra were acquired.
1 H NMR spectra were acquired using the standard one-dimensional NOESY pulse sequence, with water pre-saturation. Quantitative analysis was performed by the ChenomX software.
Mass spectrometric analysis was carried out on a Thermo Finnigan liquid chromatography/triple quadrupole mass spectrometer on electrospray ionization. The experimental conditions for the mass spectrometric analysis were the following: negative ionization mode; capillary voltage 4000 V; argon pressure 1 mTorr. For quantification purposes, data were collected in the selected ion monitoring (SIM) mode. The applicability and reliability of this analytical approach were confirmed by method validation and successful analysis of several samples with different matrices. Extraction of polyphenols from samples was performed using solid-phase extraction (SPE) Strata-X, 30 mg/1 mL (Phenomenex), a vacuum manifold, and a vacuum source.
Plasma samples polyphenolic content analysis
Plasma samples were enzymatically hydrolyzed with β-glucuronidase/sulfatase from Helix pomatia (≥ 100,000 U/mL) at 37 °C for 45 min before polyphenol extraction; analysis was performed by SPE and LC-ESI-MS/MS, respectively, as described above.
Extract microencapsulation
OLWPE extract was microencapsulated using maltodextrins and spray drying (mean particle size 10 µm) by XEDEV bvba (Zelzate, Belgium) to protect polyphenols from oxidation and heat, and simultaneously mask their unpleasant bitter taste.
Animal study
Short-term study
Male Sprague-Dawley rats (16 weeks old, weighing 400-500 g), purchased from Harlan Laboratories were used (n = 4, to attain statistical significance of at least p < 0.05, using the web resource http://www.bioma th.info/power / chsq1 gp.htm). In each animal, a single dose of the extract (containing 3.42 mg total polyphenols, corresponding to dosage 3, see below) was given by gavage, directly to the stomach. The animals were single caged, had unlimited access to food and water and were kept under normal laboratory conditions. They were closely monitored for 24 h and blood sample was collected at different time points (1, 3, 6, 18 and 24 h). The specific polyphenolic content of their plasma at different time points was determined by LC-ESI-MS/ MS under the experimental conditions described above. For each phenolic compound that has been detected the following pharmacokinetic parameters have been calculated: (1) maximum concentration (C max ), (2) time required to achieve maximum concentration (T max ), (3) area under the curve (AUC), (4) half-life (t 1/2 ), and (5) elimination rate constant (K e ), according to [12] and using PK Functions for Microsoft Excel by Joel I. Usansky (http://www.boome r.org) [13] .
Long-term study
Diets Normal food (2018S) and high-fat (HF) food (TD.06414), containing 60% Kcal from fat were purchased from Teklad, Harlan Laboratories (Supplemental Table 1 ). Both diets were acquired in their paste form so that microencapsulated OLWPE could be better incorporated. OLWPE was given in three dosages: 0.375 mg of total polyphenols (0.85 g of microcapsules per kg of food, or 0.05714 mg of total polyphenols per kg body weight per day; dosage 1, D1), 3.75 mg of total polyphenols (8.5 g of microcapsules per kg of food, or 0.5714 mg of total polyphenols per kg body weight per day; dosage 2, D2) and 37.5 mg of total polyphenols (85 g of microcapsules per kg of food, or 5.714 mg of total polyphenols per kg body weight per day; dosage 3, D3). dosage 2 corresponds to the total polyphenol content of 20 g olive oil, adjusted for rat metabolism (6 times higher dose calculated by the formula for dose translation based on body surface area-BSA, human equivalent doses (mg/kg) = animal dose (mg/kg) × animal K m /human K m , The K m factor is the body weight (kg) divided by BSA (m 2 ) as described in [14] ). This daily dose of olive oil is the dose approved by EFSA for the maintenance of normal blood cholesterol levels and protection of blood lipids from oxidation when used to replace saturated fat [15] .
Animals and experimental design Male Sprague-Dawley rats (8 weeks old, weighting 230-270 g) were purchased from Harlan Laboratories. Animals were caged in groups of 3-4 rats, had unlimited access to food and water and were kept under normal laboratory conditions. They were randomly assigned in five study groups (n = 8 animals per group to attain statistical significance of at least p < 0.05, using the web resource http://www.bioma th.info/power / ttest .htm): (1) the control group (normal diet), (2) the highfat (HF) diet group, (3) the high-fat + dosage 1 (HF + D1) group, (4) the high-fat + dosage 2 (HF + D2) group and (5) the high-fat + Dosage 3 (HF + D3) group. Rats were kept on these diets for 4 months. During this period, animals were closely monitored and their weight was measured weekly. At the start and at the end of the study, animals fasted for 12-14 h and afterward blood samples were collected, for complete blood cell counting, immunophenotyping, and biochemical analysis. When animals were sacrificed at the end of the study, selected tissues (kidney, liver, lungs, fat and heart) were also kept for histological analysis.
Animal studies were approved by the School of Medicine, University of Crete Committee for animal welfare (Protocol no. 6174 /7-5-14) and all experiments were performed in accordance with relevant guidelines and regulations.
Blood sample analysis Complete blood cell count was performed at the University Hospital of Heraklion, Laboratory of Haematology, in an Abbott Emerald Hematology (Abbott, CA, USA) analyzer, according to standard operating procedures.
Immunophenotyping was performed as follows: 100 µL of whole blood were incubated with the different fluorescently labeled antibodies for 30 min, followed by red blood cell lysis with the addition of 2 mL BD FACS Lysing solution (for a least 10 min). Afterwards, each sample was analyzed in a flow cytometer (Attune ® Acoustic Flow cytometer, Applied Biosystems, Thermo Fisher Scientific, Waltham, MA USA) using lymphocyte population of at least 5000 cells. FITC mouse anti-rat CD4 (561834), PE mouse antirat CD45 (554878), PE mouse anti-rat CD8a (559976), PE mouse anti-rat CD25 (554866), FITC mouse anti-rat CD32 (550272) and FITC mouse anti-rat CD3 (561801) were from BD Pharmingen ® (BD Biosciences, San Jose, CA USA). FITC mouse anti-rat CD19 (MA5-16536) was from Thermo Fisher Scientific (Waltham, MA USA).
Biochemical and metabolic parameters: All biochemical and metabolic parameters (glucose, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, hs-CRP, urea, creatinine, γGT, SGOT, and SGPT) were measured according to standard operating procedures using Olympus AU2700 Analyzer at the Laboratories of Biochemistry and Clinical Immunology of the University Hospital of Heraklion.
Rat Hormones and pro-inflammatory cytokines: Insulin, leptin, TNFα, and IL6 were measured in duplicate using a multiplex kit (MILLIPLEX ® MAP Rat Adipokine Magnetic Bead Panel RADPKMAG-80K-04; Millipore Corp., St. Charles, MO, USA), in a Luminex 100 apparatus.
Total antioxidant capacity (TAC): TAC was measured colorimetrically using the crocin bleaching assay as described in [16] .
Histology Toxicity was assessed using hematoxylin-eosin staining in formalin-fixed paraffin-embedded sections of selected tissues (liver, kidney) for all study groups. Histological analysis and evaluation were estimated by two independent pathologists.
Human study
Participants and study design
Thirty-five volunteers, from a rural part of the Heraklion Prefecture, Greece, without any diagnosed disease, participated in this study. Their anthropometric data are shown in Supplemental Table 2 . The study was implemented in the following phases: participant recruitment using several exclusion criteria (Supplemental Table 3 ), baseline data collection, test phase I (4 weeks), washout period (2 weeks) and a test phase II (4 weeks). Participants consumed the meat product without the microencapsulated OLWPE in test phase I and the same meat product with the microencapsulated OLWPE in test phase II. Blood sample collection and weight measurements were taken at the start of the study (baseline values, t = 0) at the end of phase I (t = 1) and at the end of phase II (t = 2). Power calculation with the web resource http://www.bioma th.info/power /chsq1 gp.htm suggested that this sample size was sufficient to detect 84% of differences, with a power probability of 0.90 and an alpha probability of 0.05.
All participants gave written informed consent to participate in the study. The study was approved by the Ethics Committee of the Heraklion University Hospital (Protocol no. 10714) and was performed in accordance with relevant guidelines and regulations.
Diet
All participants in each test phase were on a free diet (a 3-day food record at t = 0 and after phases I and II, which represents the participants' usual diet was obtained). All participants adhered to the Mediterranean diet as estimated by the Mediterranean Diet Score [17] .
Data collection
Different socio-demographic data, such as date of birth, gender, citizenship, marital status, place of residence, profession and contact information were collected along with a number of anthropometric measurements, including weight, height, waist and hip circumference; their body mass index (BMI) was also calculated. Additionally, blood pressure and pulse rate were monitored and several health habits, such as alcohol consumption, smoking, individual's medical history and the use of any medication were recorded. All patients were followed, once a week with telephone interviews and a complete physical examination at the beginning and the end of the corresponding period of intervention. At the end of each intervention period, a complete biochemical and hematology workup was performed.
Blood sample analysis
The metabolomic analysis was performed according to published protocols by Beckonert et al. [18] and Dona et al. [19] . Briefly, aliquots of human plasma (200 µL) were added in Eppendorf tubes to 400 µL of 0.9% saline solution, vortexed for 30 s, then centrifuged at 12,000g for 5 min at 4 °C and the sample (600 µL) was transferred into 5 mm NMR glass tubes [18] .
A Carr-Purcell-Meiboom-Gill spin echo sequence with pre-saturation was used for acquiring 1 H NMR spectra and obtaining the low MW metabolite profile of plasma. A diffusion-edited sequence (ledbpgppr2s1d) with bipolar gradients and LED scheme was used to suppress low MW compounds and obtain the 1 H NMR spectrum of lipoproteins [19] . Low MW metabolites were quantified in the CPMG NMR spectra using the ChenomX suite (ChenomX, SA). Both CPMG and diffusion-edited LED spectra were bucketed, and the data were used directly for metabolomics analysis, which was performed using the Simca 13.02 software package by Umetrics.
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Complete blood cell count, the levels of different biochemical and metabolic parameters (glucose, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, CRP, urea, creatinine, γGT, SGOT, and SGPT) and total antioxidant capacity (TAC) were obtained as described above. Insulin was measured according to standard operating procedures using Abbott ARCHITECT i 2000SR Analyzer at the Laboratory of Experimental Endocrinology of the University Hospital of Heraklion.
Immunophenotyping was performed as described above using the following anti-human antibodies from BD (BD Biosciences, San Jose, CA USA): anti-CD45 PERCP(554878), anti CD3FITC (555332), anti-CD4 PE 555347), anti-CD8 PE (555635), anti-CD25 FITC (555432), anti-CD19 FITC (555,412), anti-CD20 PE(555,623), anti-CD16PE (555,407), anti CD56 FITC (562,794).
Oxidized low-density lipoprotein (OxLDL) was assayed using an ELISA kit (Cloud-Clone Corp. Houston, TX, USA), according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed using SPSS, V21 (IBM Corporation, NY USA), Origin V8 (OriginLab Corporation, Northampton, USA) and Prism V6, (GraphPad Software, Inc La Jolla Inc). For two group comparisons, we used Student's T test, while for multiple group comparisons, ANOVA (assuming equal variance) was used, followed by post hoc group comparisons, after Bonferroni's correction and use of the residual variance as a common variance estimator. The threshold of p < 0.05 was retained for statistical significance.
Results
Polyphenolic characterization of OLWPE
The phenolic content of concentrated OLWPE was initially estimated as 10 mg/mL Trolox equivalents, while NMR analysis (Supplemental Fig. 1 ), revealed that the extract, as expected, contained phenolic compounds along with other larger amounts of small molecular weight chemicals, such as ethanol, lactic, succinic and acetic acid, and carbohydrates. Analysis of the phenolic area of the spectrum revealed that the main phenolic compound present was tyrosol (a phenylethanoid present in olives), along with small amounts of ligstroside and possibly elenolic acid, which is a common phenylethanoid hydrolysis product. Further analysis of the extract by the more sensitive LC-ESI-MS/MS method showed also the presence of the phenylethanoid verbascoside (a tyrosol ester), the flavanols catechol, catechin, and epicatechin, the flavones apigenin, apigenin-7-o-glucoside and luteolin, the flavonols quercetin and rutin and a number of phenolic acids such as caffeic, ferulic, gallic, 3-hydroxy-4-methoxy-cinamic, homovanillic, hippuric, coumaric, syringic, p-hydroxy-benzoic acid, protocatechuic acid (Supplemental Table 4 ).
The above extract was microencapsulated and used in the subsequent long-term metabolic studies, reported below.
Animal study
OLWPE bioavailability and absence of toxicity in an animal model
Initially, To examine the bioavailability of the phenolic compounds in the extract, rats were given a single dose (corresponding to the dose D3 of the long-term study, see below and "Methods" for further details) of OLWPE by gavage, blood was withdrawn at different time points (1-24 h) and serum was analyzed by LC-ESI-MS/MS. As soon as 1 h after treatment, several phenolic compounds were detected in animal serum (Fig. 1a) , including epicatechin, quercetin, caffeic, gallic, coumaric, homovanillic, and p-hydroxy-benzoic acid. This early appearance of phenolics in the blood suggested an early gastric absorption. For caffeic, gallic, and coumaric acid, increased levels were also detected after 18 and/or 24 h, indicating significant intestinal absorption, as well as, a possible increase due to (poly)phenol metabolism. Comparing the different AUC values, the compound with the greater bioavailability was ferulic acid, followed by p-hydroxy-benzoic and homovanillic acid. The latter being a metabolite of hydroxytyrosol possibly explains its absence from the serum of treated animals (Fig. 1b) .
Bioavailability data were also obtained during the longterm animal study, in which rats were fed with three different doses (D1 < D2 < D3) of microencapsulated OLWPE extract, for a period of 16 weeks. As shown in Fig. 1c , increased levels of rutin, caffeic and p-coumaric acid, were detected in animal serum. These compounds were also present in rats that fed only high-fat food (HF), while their levels increased dose-dependently when OLWPE was included in their diet. Moreover, in the highest extract dose (D3), hydroxytyrosol was detected, possibly as a biotransformation product of tyrosol, present in the extract. Further evidence supporting the bioavailability of OLWPE were obtained by measuring the plasma total antioxidant capacity (TAC) of the 16 weeksfed animals. TAC levels were dose-dependently increased in rats fed with different OLWPE extract; dose D3 exhibited a statistically significant increase, compared to the high-fat diet-only group (Fig. 1d) .
Finally, at the end of the long-term animal study, rat livers and kidneys were examined to rule out any signs of toxicity that could be attributed to the polyphenolic extract. For this reason, organs were removed, formalin-fixed, paraffin embedded and sectioned for hematoxylin-eosin staining.
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In Fig. 2 , such sections are presented for all study groups along with the levels of certain biochemical markers (GOT, GPT creatinine, and urea,) of liver and kidney toxicity for all study groups. No signs of toxicity were identified, while minor fatty liver infiltrates, as a consequence of high-fat diet, were not modified by OLWPE.
Effect of diets on rat weight
As shown in Supplemental Fig. 2A , the final weight, as well as total weight gain, was elevated in rats receiving HF food alone or in combination with any of the tested OLWPE doses compared to the control rats. This indicates that HF diet induced obesity and OLWPE did not have any effect on body weight per se.
OLWPE significantly modified circulating lipids and lowered insulin levels
A 16-week high-fat diet not only increased body weight but also induced additional features, compatible with induction of metabolic syndrome: increased triglycerides, glucose, insulin and LDL and lower HDL (Supplemental Fig. 2B and 2C) were observed, while total cholesterol levels did not exhibit significant differences. Enrichment of HF diet with the different doses of OLWPE significantly modified HDL and LDL levels (Fig. 3a) . HDL levels were significantly elevated in rats receiving the highest (D3) dose, while LDL levels of all experimental groups receiving polyphenolic extract were significantly lower when compared to the HF-only group. Accordingly, the HDL/LDL ratio (Fig. 3b) was elevated in rats receiving doses 1 and 2, compared to rats of the HF-only group. Additionally, insulin levels that were elevated in the HF-only group compared to the control group, were decreased back to normal levels in rats receiving all three doses of the polyphenolic extract (Fig. 3c) . Finally, leptin, that was significantly increased in HF-diet rats, was not modified significantly by OLWPE (Fig. 3d) . This finding is in accordance with the lack of differences in the body weight between the HF-only fed group and the groups with OLWPE in their diet. Similarly, no changes were observed in the levels of different pro-inflammatory cytokines examined (data not shown).
OLWPE decreased the levels of CD4 +
CD25 + T cells
Apart from the OLWPE-induced change of the aforementioned biochemical parameters, peripheral blood cell characteristics and immunophenotype were also examined. The major cell population numbers (red and white blood cells, platelets) were not affected (Supplemental Fig. 3) . A more detailed analysis of WBC revealed that lymphocytes were not affected, while granulocytes present a small, albeit nonsignificant decrease at OLWPE doses D2 and D3. In an immunophenotype analysis (Supplemental Fig. 4 ), CD4 + cell population was increased in an OLWPE-dose-dependent manner, while the CD4 + CD25 + T-regulatory cells were dose-dependently decreased by OLWPE and attained significant importance in the HF + D3 group, compared to the HF-diet-only group. All other immune cell variations did not present any significant differences among study groups.
Human study
The above-presented results from the animal study suggest that chronic consumption of OLWPE polyphenols, can improve the lipid profile of animals and reduce glucose levels and decrease insulin requirements. However, animal data are not easily extrapolated in humans, due mainly to a significantly different metabolism between the two species [14] . Therefore, to explore whether the same effect of OLWPE can be obtained in humans, we have performed a proof of concept short-term intervention study, by administering microencapsulated OLWPE polyphenols (in a dose equivalent to the D2 dose used in the animal study, as the total polyphenol content included in the daily dose of olive oil approved by EFSA) in apparently healthy individuals. However, anthropometric data revealed that 19 out of the 35 participants were overweighted/obese (BMI > 26) and 6 had a systolic blood pressure > 130 mmHg. The baseline biochemical analysis of our group revealed 14 individuals had a fasting blood glucose > 100 mg/dL, indicative of a prediabetic state, 26 presented a total cholesterol > 200 mg/dL, 21 presented LDL cholesterol > 130 mg/dL and 6 presented triglyceride levels > 100 mg/dL. However, their HDL levels were astonishingly high (mean ± SD 66.4 ± 10.7 mg/dL), compatible with a high consumption of vegetables and olive oil, typical of a Cretan diet, followed by all participants.
NMR-based plasma metabolomics
At a first approach, to identify changes in participants' metabolism when OLWPE is included in their diet, serum samples from each participant before and after a 4-week Fig. 1 a The concentration (ppb:µg/L) of the different phenolic compounds detected in the plasma of rats by LC-ESC-MS/MS at different time points (1, 3, 6, 12, 18 or 24 h) after administration of OLWPE by gavage (short-term study). GA gallic acid, EPCTCN epicatechin, p-11-BNZC p-11-benzoic acid, CA caffeic acid, HMVNLC homovanillic acid, p-CMRC: p-coumaric acid, FA ferulic acid, QRCTN quercetin. b Basic pharmacokinetic parameters of the phenolic compounds detected in OLWPE based on short-term study. C max maximum blood concentration, T max time required to achieve maximum blood concentration, AUC area under the curve "concentration vs time", t 1/2 half-life, K e elimination rate constant, initial dose: the amount of each phenolic compound in OLWPE administered, % in plasma/24 h: the percentage of each compound in OLWPE found in blood within 24 h (% AUC/initial dose). Abbreviations are the same as in a. c The concentration (ppb:µg/L) of the different phenolic compounds detected in the plasma of rats by LC-ESC-MS/MS after a 16-week consumption of the three different doses (D1, D2, D3) of microencapsulated OLWPE extract in their food (long-term study). HF high-fat diet. The parallel line to the x-axis represents the detection limit of the method for each compound. d Total plasma antioxidant capacity (TAC) of animals fed either with normal diet (control) or a high-fat diet (HF) with or without three different doses (D1, D2, D3) of microencapsulated OLWPE for 16 weeks (long-term study). Data are represented as mean ± SD and p values were calculated using ANOVA, with group comparisons performed with T tests and the residual variance as a common estimator of variance. Significant differences are presented, after Bonferroni correction (at least p < 0.05). Comparison with HF (*), with D1 (#) or with D2 (@) ◂ OLWPE consumption were analyzed by NMR-based metabolomics [20] [21] [22] [23] . An initial approximation of serum lipids and water-soluble metabolites (see "Methods" for details) of the participants, indicated that the serum metabolite profile was modified after OLWPE consumption (not shown). However, a much clearer separation was obtained when normoglycemic or normolipidemic individuals were excluded, and the analysis performed in the sub-group of individuals with at least two biochemical or anthropometric elements of cardio-metabolic risk (high-risk group, Fig. 4a ). OLWPE consumption was reflected in the water-soluble (R2X: 0.83 Q2X: 0.50 before and after intervention respectively) and the serum lipid profile (R2X = 0.91, Q2X = 0.69, Fig. 4a) , with the serum lipids OPLS-DA model demonstrating a better discriminatory power, in agreement with recent studies suggesting the use of methyl lipoprotein NMR region to quantify the serum lipoprotein profile [24] .
OLWPE decreased glucose and lipid levels
Based on the above metabolomic results and the beneficial effect of the microencapsulated OLWPE in animals, the lipidemic and glycemic profile of the human participants was further explored. In normoglycemic or normolipidemic individuals, the administration of the product did not modify blood glucose and lipid levels (not shown). However, in the sub-group of individuals with at least two biochemical or anthropometric elements of cardio-metabolic risk (n = 18), we observed (Fig. 4b) that administration of OLWPE in a food matrix significantly reduced elevated glucose (p < 0.002, n = 15) and insulin levels (p < 0.03, n = 6, paired analysis). In addition, OLWPE administration significantly reduced elevated total cholesterol (p < 0.009, n = 14), triglyceride (p < 0.005, n = 5) and LDL levels (p < 0.01, n = 5), while it decreased significantly oxLDL (p < 0.01, n = 18). Although HDL concentration and plasma antioxidant activity were very high and not significantly modified by the intervention (both in the whole group of participants and in the sub-group with high glucose or altered circulating lipids), possibly due to a primary impact of the Mediterranean/Cretan diet (not shown), oxLDL was also significantly reduced in the normolipidemic individuals (paired T test, p = 0.0082, n = 18), presumably as a result of the ingestion of polyphenols present in the extract.
Moreover, in the immunophenotype analysis (Supplemental Fig. 5 ), no changes were observed in the major lymphocyte populations after OLWPE consumption. However, it should be noted that obese individuals had a slightly increased CD4 + CD25 + T regulatory cells as expected from the animal study. Possibly, the inability of OLWPE to decrease them could be attributed to the dose administered that corresponds to dose 2 of the animal model that equally had no significant effect on the different cell populations.
In all participants, no modification of circulating hepatic enzymes (SGOT, SGPT), urea or creatinine levels was observed (not shown), ensuring that this product did not express any apparent hepatic or renal toxicity, at least for the period of its administration. Furthermore, no significant modification of body weight was observed, as expected, in the 1-month interval of OLWPE consumption.
Discussion
Polyphenols (more than 8000 identified molecules containing a phenolic scaffold) constitute a large family of plantderived compounds. They exhibit powerful antioxidant properties, in parallel with a large number of biological actions, depending on their absorption and metabolism [25, 26] . A variable amount of ingested polyphenols can be found in blood [27] and can interfere with major cellular processes having a beneficial impact on cancer (reviewed in [25] ), vascular function [28, 29] , and metabolism [30, 31] .
The beneficial role of olive oil consumption is widely recognized, with the European Food Safety Authority (EFSA) approving two health claims regarding olive oil [15] . They suggest its use to replace saturated fats to keep normal blood cholesterol levels and protect blood lipids from oxidative stress, with the later effect to be achieved by olive oil polyphenols contained in a daily intake of 20 g of olive oil. In numerous studies, diets enriched either in extra virgin olive oil or following the pattern of the Mediterranean diet (which is per se rich in olive oil, vegetables and legumes) have provided further evidence about the beneficial role of plant and olive oil antioxidant fractions in the prevention of cardiovascular disease [32] , diabetes [9, [33] [34] [35] and hyperlipidemia [8] . In fact, a meta-analysis of 50 studies and 534,906 individuals revealed that adherence to the Mediterranean diet was associated with reduced risk of metabolic syndrome [36] . Additionally, the intervention study PRED-IMED (PREvencion con DIeta MEDiterranea) demonstrated the beneficial effect of the Mediterranean diet on the prevention of cardiovascular disease [37, 38] . More recently, it was shown that the Mediterranean diet participants in the Fig. 2 a Changes in the concentration of the hepatic enzymes SGOT and SGPT in animals fed either with normal diet (control) or a highfat diet (HF) with or without three different doses (D1, D2, D3) of microencapsulated OLWPE for 16 weeks. Data are represented as mean ± SD. b Representative microphotographs of hematoxylin-eosin stained liver sections of animals from the different study groups. Blue arrows indicate fat infiltration of the liver. c Changes in the concentration of the urea and creatinine in animals fed either with normal diet (control) or a high-fat diet (HF) with or without three different doses (D1, D2, D3) of microencapsulated OLWPE for 16 weeks. Data are represented as mean ± SD. d Representative microphotographs of hematoxylin-eosin-stained kidney sections of animals from the different study groups. Bars = 100 µΜ ◂ PREDIMED study had lower concentrations of inflammatory markers related to atherosclerosis, explaining in part its cardioprotective effect [39] . Moreover, in an animal obesity and diabetes model, a polyphenol-enriched extract from olive leaves has been shown to reverse the chronic inflammation and oxidative stress that induces a cardiovascular, hepatic, and metabolic dysfunction [10] .
Olives are a rich source of polyphenols; during their harvesting and olive oil extraction, contained polyphenols are distributed between the oil and water phase, depending on the malaxation time and the applied temperature. Therefore, this water phase is a rich source of olive polyphenols, not yet exploited as a beneficial constituent of human functional foods/medicinal preparations, although its polyphenol ANOVA was used for statistical evaluation, and group differences were calculated after Bonferroni correction and with the residual variance as a common estimator of variance. Significant differences are reported 1 3 spectrum may differ from that of olive oil, due to a continuous enzymatic activity in the water extract and the different oil/water partition coefficient of each polyphenolic molecule. At this point, it needs to be stressed that, although hydroxytyrosol, present in olive fruit and oil has been reported to confer amelioration of metabolic syndrome and cardioprotection in a diet-induced rat model of metabolic syndrome [40, 41] , a number of studies, point out that the beneficial effect is maximized when the total extract is used [42, 43] . This suggests: (1) either a synergistic effect of polyphenol molecules, that cannot be totally mimicked by the artificial combination of isolated phenolic molecules; or (2) that the effect of the extract is attributed to minor constituents, present in the total extract, beyond the lead molecules identified so far. Furthermore, an interesting observation that is in favor of the use of total plant extracts, is that isolated phenolic molecules with antioxidant properties (including vitamin C) may induce prooxidant activities, when administered isolated in vitro or in vivo [44, 45] , while a clear antioxidant effect was present when administered in a food matrix [46] . Based on the above arguments, in our study, we used the total polyphenolic water extract from olives (OLWPE), that contains a number of different phenolic compounds (phenylethanoids, flavones, flavanols, and phenolic acids-see "Results" for details) and at a more physiological dose compared to the one for hydroxytyrosol, utilized by Poudyal et al. in the their study [41] . Our dose is similar to the amount of phenolics that someone can take from 20 g of olive oil daily. Our findings can be summarized as follows: (1) we have shown that polyphenols and simple phenolic products could be absorbed from different parts of the GI tract, as derived from acute metabolic studies in rats; (2) the profile of absorbed polyphenols after chronic administration was different from that of an acute one; (3) both in obesity-metabolic syndrome animal model and in humans, chronic administration of OLWPE in a food matrix resulted in improvement of glycemic control and lipid metabolic parameters, with no apparent toxicity; (4) in the chronic animal model, OLWPE normalized the number of circulating CD4 + CD25 + T regulatory cells that have been elevated in the metabolically dysfunctional high-fat-fed animals.
In our experimental conditions, animals fed with the high-fat diet were significantly overweighed compared to those fed with a normal fat diet and exhibited metabolic dysfunction characterized by increased cholesterol, triglyceride, LDL and insulin levels, suggesting the establishment of insulin resistance. The effect of OLWPE was examined at three different doses, with dose 2 corresponding to the total polyphenol content of 20 g olive oil, adjusted for rat metabolism as described by Reagan-Shaw ët al. [14] (see "Methods" for further details). OLWPE ameliorated a number of the high-fat diet-modified metabolic parameters, such as lipidemic and glycemic profile, with a lack of toxicity.
These results are in accordance with a previous study on the effect of olive mill water biophenols on alloxan-induced diabetic rats [47] . Especially in the case of increased LDL and decreased HDL levels, OLWPE seemed to exhibit a highly beneficial effect. Additionally, even though fasting glucose was not significantly reduced, OLWPE reduced diet-induced hyperinsulinemia. Another interesting finding was that OLWPE could restore circulating CD4 + and CD4 + CD25 + T regulatory cells, that have been reduced and elevated respectively by high-fat diet, back to normal levels. CD4 + CD25
+ T regulatory cells are important anti-inflammatory cells; however, their proportion of obesity-related metabolic disturbances is still controversial. There are studies reporting a reduction in obesity [48] [49] [50] and others, including our findings, an increased number of peripheral blood Tregs [51] . In fact, their percentage seems to be interdependent to their concentration in inflamed tissues. For instance, inflamed obese visceral adipose tissue has been shown to have a reduced proportion of Tregs [52, 53] and that could be a possible explanation for their increased number in the blood.
The above-presented effects of OLWPE were greatly supported by our findings that the phenolic compounds of the extract were bioavailable (detected in rats' sera) and the fact that the animals treated with the extract exhibited increased total plasma antioxidant capacity. Indeed, several phenolic compounds present in the extract were detected in the blood of the animals (epicatechin, quercetin, caffeic, gallic, coumaric, homovanillic, and p-hydroxy-benzoic acid) as early as 1 h after ingestion, pointing out an additional gastric absorption, that was followed by intestinal absorption [54] . Interestingly, samples collected at longer time points after the OLWPE administration showed significant levels of hydroxytyrosol. The later could be the result of biotransformation of tyrosol to hydroxytyrosol by CYP2D6 and CYP2A6 as has been recently described [55] . However, the aforementioned effects of OLWPE cannot be solely attributed to the detected molecules, due to certain limitations such as the doses used and the detection limit of the LC-ESCI-MS/MS method. Nevertheless, our data present a proof of the bioavailability of the polyphenolic olive extract, as previously described [56] .
Obesity in humans is considered an emerging health problem [57] and in spite of the number of studies, its prevalence continues to rise. Diet is certainly very important to obesity incidence, to the metabolic dysfunction that usually occurs in obese individuals and to its negative consequences, such as cancer [58] , aging [59] , cardiovascular disease [60] and a number of other pathologies [61] . Metabolic dysfunction includes changes in lipid and glucose metabolism, characterized by increased LDL cholesterol and low HDL levels, high glucose and insulin levels that can result to endothelial dysfunction, atherosclerosis and subsequent heart disease [62] . It is, therefore, of great importance to find and exploit substances that will improve the above metabolic parameters. When healthy young individuals consumed OLWPE daily for a period of 4 weeks, metabolomic analysis revealed clear differences in their lipid and water-soluble metabolites, compared to the period that they did not consume OLWPE. Furthermore, a significant amelioration of specific metabolic parameters was observed in those individuals identified with elevated cardio-metabolic risk factors (at least 2 factors among fasting glucose and insulin, triglycerides, total and LDL cholesterol, n = 18). These findings are in accordance with previous studies that reported a beneficial effect of olive oil and its phenolic constituents on lipid profile [16, [63] [64] [65] [66] [67] . HDL and total antioxidant capacity were very high and not modified by OLWPE; however, oxidized LDL (a better index of oxidative damage which is known to actively participate in atheromatous plaque formation and atherosclerosis) was significantly decreased in OMWPE-treated individuals, supporting the beneficial effect of OLWPE on cardiovascular risk factors. Additionally, it is of great importance that with the inclusion of OLWPE in the diet (both in animals and humans) a normal insulin sensitivity was restored. In fact, it is the first study reporting a direct effect of olive water extract polyphenols on fasting glucose and insulin levels in humans at dietary concentrations, while all previous studies were either conducted with olive oil (see for example [68] , for a recent publication) or with a single phenolic compound such as hydroxytyrosol in an animal model [41] but at concentrations that can be characterized as pharmacological ones, when translated from animals to humans. Finally, even though overweighted/obese individuals exhibited an increase in peripheral blood CD4 + CD25 + T regulatory cells (as also observed in the animal model), OLWPE consumption had no effect, mainly due to the given dose (which was also ineffective in animals) and duration of the study.
Overall, we conclude that OLWPE can exhibit a beneficial health effect, mainly by modifying circulating lipids and glucose/insulin levels, and most importantly without the presence of monounsaturated fats of olive oil, on which there are contradictory data concerning their role on development of insulin resistance, type 2 diabetes mellitus and impaired vascular integrity and cardiovascular disease [69] [70] [71] [72] . Under this scope, we suggest that this microencapsulated polyphenolic extract could possibly be used in the development of "functional" OLWPE polyphenol-enriched foods or as an alternative natural/adjuvant therapeutic approach in hyperlipidemia and impaired glucose/insulin regulation. Fig. 4 a OPLS-DA models of 1 H NMR spectroscopy obtained serum lipid and water-soluble metabolite profiles of individuals (n = 17) after consumption of a plain meat product (green) and one supplemented with OLWPE microencapsulated polyphenols (blue). b The lipidemic and glycemic profile of individuals with at least two biochemical or anthropometric elements of cardio-metabolic risk (n = 18) when consumed the meat product with the microencapsulated extract (OLWPE+) compared to their profile when the meat product was without the microencapsulated extract (OLWPE−). Data are represented as mean ± SD. Statistical evaluation was performed with paired T test. Significant statistical differences are reported in the graphs ◂
